Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Ashok Kumar, David P. Brennan, Karima Chafai-Fadela, Sylvia A. Holden, Siya Ram, Geoffrey I. Shapiro, Krishna Menon | ||||||||||||
Title | Kevetrin induces p53-dependent and independent cell cycle arrest and apoptosis in ovarian cancer cell lines representing heterogeneous histologies | ||||||||||||
|
|||||||||||||
URL | http://www.abstractsonline.com/pp8/#!/4292/presentation/3876 | ||||||||||||
Abstract Text | Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 del | ovarian clear cell carcinoma | predicted - sensitive | thioureidobutyronitrile | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment resulted in Tp53-independent increase of Cdkn1a expression and apoptosis of ovarian clear cell carcinoma cells harboring TP53 deletion in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221). | detail... |
TP53 mutant | ovarian serous carcinoma | sensitive | thioureidobutyronitrile | Preclinical - Cell culture | Actionable | In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment decreased mutant Tp53 level, resulted in apoptosis of ovarian serous carcinoma cells harboring TP53 mutations in culture (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221). | detail... |
TP53 wild-type | endometrioid ovary carcinoma | sensitive | thioureidobutyronitrile | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221). | detail... |